Advertisement

Topics

Latest Gastroenterology NewsRSS

12:48 EST 21st November 2017 | BioPortfolio

New study results support use of DiviTum® TK1 biomarker assay for evaluation of pancreatic cancer

Uppsala, Sweden, November 21, 2017. In collaboration with University of Heidelberg, Germany, results from a clinical study of pancreatic cancer is published in the Pancreas scientific journal. The results demonstrate that Biovica’s DiviTum assay can provide an accurate prognosis and evaluation of treatment efficacy. The proof of concept study, including 404 patients, provides evidence f...

Why does testicular cancer respond better to chemotherapy? Stem cells

Why does testicular cancer responds better to chemotherapy? Stem cells

Syros to Present at 29th Annual Piper Jaffray Healthcare Conference

Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the development of medicines to control the expression of disease-driving genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a fireside chat at the 29th Annual Piper Jaffray Healthcare Conference. Details are as follows: 29t...

Cancer Prevention Pharmaceuticals to Present at the 29th Annual Piper Jaffray Healthcare Conference

CEO to give update on clinical pipeline and lead drug CPP-1X Cancer Prevention Pharmaceuticals (CPP), a clinical stage biotechnology company, today announced it will give a corporate presentation at the Piper Jaffray 29th Annual Healthcare Conference on November 28, 7:50-8:10 a.m. ET at the Lotte New York Palace in New York City (Track Seven: Kennedy 2...

Constellation Pharmaceuticals to Present at Piper Jaffray Healthcare Conference

Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing tumor-targeted and immuno-oncology therapies based on its pioneering research in cancer epigenetics, today announced that President and Chief Executive Officer Jigar Raythatha will present a company overview at the 29th Annual Piper Jaffray Healthcare Conference on N...

The Leukemia & Lymphoma Society Funds $46M In New Research

NewsThe Leukemia & Lymphoma Society has invested more than $1 billion in cancer research in its nearly 70-year history. With the society's help and assistance by other groups, the FDA has approved more than a dozen blood cancer therapies in 2017.

The Leukemia & Lymphoma Society Funds $46 M In New Research

NewsThe Leukemia & Lymphoma Society has invested more than $1 billion in cancer research in its nearly 70-year history. With the society's help and assistance by other groups, the FDA has approved more than a dozen blood cancer therapies in 2017.

CRISPR Editing Creates TCR Swap-Shop for Cancer Immunotherapy

A team at Cardiff University in the U.K. has used CRISPR/Cas9 genome editing to generate engineered killer T cells that are up to a thousand times more sensitive to cancer cell antigens than T cells engineered using more conventional approaches, and which allowed far better targeting of T cells to cancer cell lines and patient-derived leukemia cells. The new approach exploits the genome-editin...

Global Biomarker Technology Platforms for Cancer Diagnoses and Therapies Market Research Report Forecast 2017 to 2022 [Report Updated: 01011970] Prices from USD $2800

Delivery of the Report will take 23 working days once order is placed.The Global Biomarker Technology Platforms for Cancer Diagnoses and Therapies Market Research Report Forecast 20172022 is a valuable source of insightful data for business strategists. It provides the Biomarker Technology Platforms for Cancer Diagnoses and Therapies industry overview with growth analysis and historical futuris...

Gastric CancerEpidemiology Forecast to 2025 [Report Updated: 10102017] Prices from USD $2200

DelveInsight Gastric Cancer Epidemiology Forecast To 2025 provides an overview of the epidemiology trends of Gastric Cancer in seven major markets US, France, Germany, Italy, Spain, UK and Japan. It includes 10 years epidemiology historical and forecasted data of Gastric Cancer prevalent or incident cases segmented by age, sex and subpopulations. The Report also discusses the prevailing risk fact...

Oncobiologics Inc ONSIU Financial and Strategic SWOT Analysis Review [Report Updated: 13112017] Prices from USD $300

SummaryOncobiologics Inc Oncobiologics is a biopharmaceutical company that develops and markets biosimilar therapeutics. The company's product pipeline comprises ONS3010 and ONS1045. It uses biosymphony platform to overcome technical and regulatory challenges in developing and commercializing mAb biosimilars. Oncobiologics' adalimumab is used in the treatment of rheumatoid arthritis, ulcerative co...

Ureter Cancer Pipeline Review, H2 2017 [Report Updated: 31102017] Prices from USD $2000

Ureter Cancer Pipeline Review, H2 2017SummaryGlobal Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ureter Cancer Pipeline Review, H2 2017, provides an overview of the Ureter Cancer Oncology pipeline landscape.Ureter cancer or ureteral cancer is cancer of the ureter. Symptoms and signs of urethral cancer include bleeding from the urethra or blood in the urine, discha...

What can genomics and tumours teach us about cancer drug development?

Non-small cell lung cancer (NSCLC) is big news this morning with the announcement from Genentech/Roche that the IMpower150 trial exploring…

Roche’s Potential Hemophilia Blockbuster and Lung Cancer Drug Succeed in the Clinic

Roche has enjoyed a dream start to the week with both its immuno-oncology candidate, Tecentriq, and its hemophilia A drug, Hemlibra, succeeding in the clinic. Roche’s week started with a bang as two of its drug candidates achieved positive results ... This awesome article Roche’s Potential Hemophilia Blockbuster and Lung Cancer Drug Succeed in the Clinic appeared first on Labiotech.eu. Be kind...

GRACE Needs Your Help

Please consider providing a tax-deductible gift this year. Your needed support, now more than ever, will ensure we continue to provide the best information about cancer arguably available anywhere, for patients and caregivers who so desperately need it.Related Posts:One Patient’s Plea on “Giving… December 2, 2014

AJCC Confirms MammaPrint’s Clinical Utility for Treatment Decisions and Staging in Recent 8th Edition Breast Chapter Update

Update clarifies that the patient and clinician may choose any genomic profile or multigene panel based on available clinical evidence at the time of treatment In line with recent publications from NEJM and ASCO, the AJCC now recognizes MammaPrint with Level I evidence for determining clinical prognosis, which is the basis f...

AJCC Confirms MammaPrint's Clinical Utility for Treatment Decisions and Staging in Recent 8th Edition Breast Chapter Update

Update clarifies that the patient and clinician may choose any genomic profile or multigene panel based on available clinical evidence at the time of treatment In line with recent publications from NEJM and ASCO, the AJCC now recognizes MammaPrint with Level I evidence for determining clinical prognosis, which is the basis for chemotherapy treatment decisions Irvine, CA, USA and Amsterdam, the ...

Global Medical Devices Company, MEL MEDICAL Enterprises, Modernizes Clinical Research with Multi-Year Medidata eTMF Agreement

Company Accelerates Bladder Cancer Research by Unifying Content, Data, and Workflows Medidata (NASDAQ: MDSO), the leading global provider of cloud-based solutions and data analytics for clinical research, today announced that

Fabry Disease Market Insights, Epidemiology and Market Forecast 2025 [Report Updated: 10112017] Prices from USD $4600

DelveInsight's Fabry Disease Market Insights, Epidemiology and Market Forecast 2025 report provides an overview of the disease and in depth research related to Fabry Disease for the 7MM United States, Germany, France, Italy, Spain and UK for the study period undertaken from 20152025. This report provides understanding of the patients affected, diagnosed patterns, treatment trends, unmet medica...

Prescient Therapeutics (PTX) - PTX-100 to target RhoA-mutant lymphomas

Edison Investment Research - Pharmaceutical & healthcare - Prescient Therapeutics: Prescient Therapeutics is planning a clinical trial of PTX-100 in RhoA-mutant lymphomas, a niche indication where the company could potentially conduct a pivotal study before out-licensing. It has resumed recruitment in the Phase Ib component of trials of lead anti-cancer compound PTX-200 in acute myeloid leukaemia ...

High BMI linked to larger breast cancer tumor size

BMI was the only consistent risk factor for detecting breast tumors larger than 2 cm among women, according to findings being presented at next week’s annual meeting of the Radiological Society of North America.“Ever since breast cancer screening was introduced there has been a debate about its utility,” Fredrik Strand, MD, radiologist at the Karolinska University Hospital in Stockholm, Swed...

A Cancer Cell’s Weight Predicts Its Therapeutic Opponent

Scientists in the U.S. have shown how measuring changes in the weight of individual living cancer cells taken from multiple myeloma (MM) patients can accurately predict whether their cancer will respond to different drug treatments. The microfluidic device, known as a suspended microchannel resonator (SMR), is capable of weighing cells 10 to 100 times more accurately than any other existing method...

Huntington's Disease Market Insights, Epidemiology and Market Forecast 2025 [Report Updated: 10102017] Prices from USD $4600

DelveInsight's Huntington's Disease Market Insights, Epidemiology and Market Forecast Market Insights, Epidemiology and Market Forecast 2025 report provides an overview of the disease and in depth research related to Huntington's Disease Market Insights, Epidemiology and Market Forecast for the 7MM United States, Germany, France, Italy, Spain and UK for the study period undertaken from 2015202...

Lyme Disease in the United States — Good News, Bad News

The incidence of Lyme disease appears to have stabilized in states with known high incidences of the infection, but there is evidence of geographic expansion into neighboring states.

Quick Search
Advertisement
 

review and buy Gastroenterology market research data and corporate reports here